FY2024 EPS Estimates for Immuneering Co. (NASDAQ:IMRX) Boosted by Chardan Capital

Immuneering Co. (NASDAQ:IMRX) – Equities research analysts at Chardan Capital increased their FY2024 EPS estimates for Immuneering in a note issued to investors on Monday, September 16th. Chardan Capital analyst G. Livshits now anticipates that the company will post earnings per share of ($1.61) for the year, up from their previous estimate of ($1.64). Chardan Capital currently has a “Buy” rating and a $12.00 price target on the stock. The consensus estimate for Immuneering’s current full-year earnings is ($1.90) per share. Chardan Capital also issued estimates for Immuneering’s FY2025 earnings at ($0.75) EPS.

Separately, Needham & Company LLC reissued a “buy” rating and issued a $15.00 price target on shares of Immuneering in a research report on Friday, September 13th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.60.

Immuneering Stock Performance

Shares of IMRX opened at $2.28 on Wednesday. The firm has a market cap of $67.61 million, a PE ratio of -1.22 and a beta of -0.61. The firm’s 50 day moving average price is $1.26 and its 200 day moving average price is $1.82. Immuneering has a twelve month low of $1.00 and a twelve month high of $9.00.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.47) earnings per share for the quarter, beating the consensus estimate of ($0.52) by $0.05.

Hedge Funds Weigh In On Immuneering

A number of institutional investors have recently modified their holdings of IMRX. Vanguard Group Inc. grew its stake in shares of Immuneering by 12.1% in the first quarter. Vanguard Group Inc. now owns 1,203,666 shares of the company’s stock worth $3,479,000 after acquiring an additional 129,851 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Immuneering in the second quarter worth $67,000. Renaissance Technologies LLC acquired a new stake in shares of Immuneering in the second quarter worth $447,000. XTX Topco Ltd grew its stake in shares of Immuneering by 37.3% in the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock worth $44,000 after acquiring an additional 9,274 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Immuneering in the second quarter worth $492,000. Institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.